These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 26678339)

  • 21. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.
    Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
    Izquierdo-Garcia JL; Viswanath P; Eriksson P; Cai L; Radoul M; Chaumeil MM; Blough M; Luchman HA; Weiss S; Cairncross JG; Phillips JJ; Pieper RO; Ronen SM
    Cancer Res; 2015 Aug; 75(15):2999-3009. PubMed ID: 26045167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NAD
    Kennedy BE; Sharif T; Martell E; Dai C; Kim Y; Lee PW; Gujar SA
    Pharmacol Res; 2016 Dec; 114():274-283. PubMed ID: 27816507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
    Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
    Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP
    Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner.
    Takeuchi M; Yamamoto T
    Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
    Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
    BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
    Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
    Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
    Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
    Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.